RFCA
ESPR icon

R&F Capital Advisors’s Esperion Therapeutics ESPR Stock Holding History

R&F Capital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$244K Buy
+6,914
New +$158K 0.06% 480

Other funds holding ESPR

Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

R&F Capital Advisors's ESPR Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Esperion Therapeutics (ESPR) in Q1 2017: 6,914 shares worth $244K. The stake represents 0.06% of the portfolio and ranks #480 among its holdings.

119 funds tracked by Wall St. Rank hold ESPR as of Q1 2017.

  • R&F Capital Advisors held 6,914 shares of Esperion Therapeutics worth $244K as of Q1 2017.
  • Esperion Therapeutics was a new R&F Capital Advisors position in Q1 2017.
  • Esperion Therapeutics made up 0.06% of R&F Capital Advisors's portfolio in Q1 2017, its #480 holding.
  • 119 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.